Form 10-Q · Quarterly report
Charles River Laboratories 10-Q, filed Aug 5, 2026
- Filed
- CIK
- 0001100682
- Accession no.
- 0001100682-26-000118
Summary
Charles River Laboratories reported second-quarter fiscal 2026 revenue of $1.004 billion, down 2.7% from a year earlier, while operating income rose to $119.9 million, amid a cautious but improving client spending environment it said persisted in its Discovery and Safety Assessment segment. The company also detailed recent portfolio moves, including the acquisitions of PathoQuest and Cambodian non-human primate supplier assets and the divestitures of its European Discovery Services businesses to IQVIA and its CDMO and Cell Solutions businesses to GI Partners.
Key points
- Revenue for the quarter ended June 27, 2026 fell 2.7% to $1.004 billion from $1.032 billion a year earlier, with operating income of $119.9 million versus $100.1 million.
- Charles River completed the $67.6 million purchase of an additional 79% equity interest in PathoQuest SAS on April 17, 2026, and the $507.3 million acquisition of certain K.F. Cambodia Ltd non-human primate supplier assets on January 14, 2026.
- It sold certain European Discovery Services businesses to IQVIA for $125.2 million on May 22, 2026, and its CDMO and Cell Solutions businesses to GI Partners on May 6, 2026, recording a $181.7 million loss on the latter divestiture for the six-month period.
- The company said cost-savings and restructuring actions are expected to produce about $300 million in cumulative annualized savings by the end of 2026, and reported Discovery and Safety Assessment backlog of $2.0 billion as of June 27, 2026 versus $1.9 billion at the end of 2025.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
From the filing
Item 2. Management’s Discussion Overview We are a leading, full service, non-clinical global drug development partner. For over 75 years, we have been in the business of providing the research models required in the research and development of new drugs, devices, and therapies. Over this time, we have built upon our original core competency of laboratory animal medicine and science (research model technologies) to develop a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP, that supports our clients from target identification through non-clinical development. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.